max dose on semaglutide 🟣 FDA Approves Wegovy HD (semaglutide 7.2 mg) — the highest-dose GLP-1 RA yet for chronic weight management in adults with obesity or overweight + ≥1 weight-related condition. 🟣 Lightning-fast approval in How to Take Ozempic® Pill

Established risk factors for venous thromboembolism (VTE) include: Obesity (BMI 30 kg/m), which increases venous stasis and pro-inflammatory states Immobility or reduced mobility , particularly relevant in patients with severe obesity Previous history of VTE or family history of thrombophilia Active malignancy or recent surgery Hormonal therapies , including combined oral contraceptives or hormone replacement therapy Pregnancy and the postpartum period Smoking , which affects endothelial function and coagulation Risk factors for arterial thrombosis (myocardial infarction, stroke) include: Type 2 diabetes mellitus , associated with endothelial dysfunction, platelet hyperreactivity, and a prothrombotic state Hypertension , causing arterial wall damage Dyslipidaemia , promoting atherosclerotic plaque formation Established cardiovascular disease Chronic kidney disease , common in diabetes and associated with increased cardiovascular risk Patients initiating GLP-1 therapy should undergo a comprehensive cardiovascular risk assessment

It reduces confusion with controlled substances

This triple mechanism distinguishes it from existing approved treatments such as semaglutide (which targets GLP-1 alone) or tirzepatide (which targets GLP-1 and GIP)

Eggs, Greek yogurt, or protein smoothies work well